LV12736A - Method for producing concentrated antigen composition against swine erysipelas disease - Google Patents

Method for producing concentrated antigen composition against swine erysipelas disease

Info

Publication number
LV12736A
LV12736A LV000047A LV000047A LV12736A LV 12736 A LV12736 A LV 12736A LV 000047 A LV000047 A LV 000047A LV 000047 A LV000047 A LV 000047A LV 12736 A LV12736 A LV 12736A
Authority
LV
Latvia
Prior art keywords
swine
immunization
swine erysipelas
against swine
disease
Prior art date
Application number
LV000047A
Other versions
LV12736B (en
Inventor
Aleksandrs Jemeljanovs
Viktors Mozgis
Janis Bluzmanis
Original Assignee
Sigra Llu Zinatnes Centrs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigra Llu Zinatnes Centrs filed Critical Sigra Llu Zinatnes Centrs
Priority to LVP-00-47A priority Critical patent/LV12736B/en
Publication of LV12736A publication Critical patent/LV12736A/en
Publication of LV12736B publication Critical patent/LV12736B/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention belongs to veterinary medicine, especially to bacteriology and immunology. It may be used for producing antigen against infectious swine diseases caused by Erysipelothrix Rhusiopathiae. The mentioned antigen made by cultivation of Erysipelothrix Rhusiopathiae in Hottinger's medium could be used for immunization of donors (horses, young stock or swine) selected for producing hyper-immune serum against swine erysipelas disease. Animal immunization using concentrated antigen against swine erysipelas disease produced according to mentioned invention guarantees obtaining serum characterised by higher antibody titre. That serum causes no acute anaphylaxis and reduces required number of active immunization.
LVP-00-47A 2000-04-18 2000-04-18 Method for producing concentrated antigen composition against swine erysipelas disease LV12736B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LVP-00-47A LV12736B (en) 2000-04-18 2000-04-18 Method for producing concentrated antigen composition against swine erysipelas disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-00-47A LV12736B (en) 2000-04-18 2000-04-18 Method for producing concentrated antigen composition against swine erysipelas disease

Publications (2)

Publication Number Publication Date
LV12736A true LV12736A (en) 2001-10-20
LV12736B LV12736B (en) 2001-12-20

Family

ID=19735172

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-00-47A LV12736B (en) 2000-04-18 2000-04-18 Method for producing concentrated antigen composition against swine erysipelas disease

Country Status (1)

Country Link
LV (1) LV12736B (en)

Also Published As

Publication number Publication date
LV12736B (en) 2001-12-20

Similar Documents

Publication Publication Date Title
Masson et al. Calcium phosphate: a substitute for aluminum adjuvants?
Leitner et al. Development of a Staphylococcus aureus vaccine against mastitis in dairy cows. II. Field trial
NZ611563A (en) Human antibodies that bind human il-12 and methods for producing
DE69535243D1 (en) AGAINST HUMAN INTERLEUKIN-8 DIRECTED, RECONSTITUTED HUMAN ANTIBODY
BRPI0113110C8 (en) Anti-tnf antibody and composition comprising it
BR0113112A (en) Antibodies, antidual integrin, compositions, methods and uses
HUP0402653A2 (en) Human antibodies specific for interleukin 15 (il-15)
DK0654086T3 (en) Vaccines against Aujeszky's disease and other animal diseases containing mutants of pseudo-rabies virus
ATE150976T1 (en) VACCINE CONJUGATES FOR THE TREATMENT OF BIRD DISEASES
EA200301324A1 (en) MYCOPLASMA BOVIS VACCINE AND METHODS OF REDUCING PNEUMONIA IN ANIMALS
PT93966A (en) NEW SYSTEM OF LIBERATION OF ANTIBODIES FOR BIOLOGICAL RESPONSE MODIFIERS
Horzinek Vaccine use and disease prevalence in dogs and cats
BR9713312B1 (en) veterinary vaccine preparation useful for producing active immunity against a bacterial or protozoal disease.
NO913428L (en) HUMANT INTRA-ACROSOMAL SPERMA ANTIGEN FOR USE IN A FERTILIZATION PREVENTION VACCINE.
ATE196425T1 (en) VACCINE AGAINST LYME DISEASE
ES2156932T3 (en) MICROPARTICLES LOADED WITH ANTIGEN AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE MICROPARTICLES.
BR0110278A (en) A vaccine, antibody or antiserum composition, methods of producing an antibody or antiserum and immunizing an animal against a blood-eating ectoparasite, tick cement protein, and use of a protein tick cement
LV12736A (en) Method for producing concentrated antigen composition against swine erysipelas disease
WO2001049319A8 (en) Composition containing bacterial antigens, used for the prophylaxis and the treatment of allergic diseases
NZ544453A (en) Vaccine composition for vaccinating dogs against canine infectious respiratory disease (cird)
RU2462263C2 (en) Use of bacterium clostridium perfringens type c for producing vaccine
DK0485463T3 (en) Impaired canine parvovirus (CPV), vaccine comprising CPV and method of preventing CPV infection in dogs
ES2169153T3 (en) BROADLY REAGENT OPSONIC ANTIBODIES THAT REACT WITH COMMON STAPHILOCOCIC ANTIGENS.
Bastianello, SS* & Spencer A report of swine erysipelas in a litter of piglets
Auge de Mello et al. Field application of inactivated oil adjuvanted foot-and-mouth disease virus vaccine: vaccination and revaccination of young cattle